SCHEMBL5543148

SCHEMBL5543148

O=[C]OCc1ccc([N+](=O)[O-])o1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.53
L3MBTL1 Q9Y468 4/20 0.39
TDP1 Q9NUW8 3/20 0.39
KMT2A Q03164 2/20 0.39
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
MITF O75030 1/20 0.39
MAPT P10636 1/20 0.39
XBP1 P17861 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
POLB P06746 3/20 0.37
HTT P42858 2/20 0.35
NFKB1 P19838 1/20 0.35
RECQL P46063 1/20 0.35
BLM P54132 1/20 0.35
NFKB2 Q00653 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5536802 0.83 LMNA (0.50) LMNAL3MBTL1TDP1KMT2AALDH1A1
SCHEMBL5539126 0.81 LMNA (0.47) LMNAL3MBTL1TDP1KMT2AALDH1A1
SCHEMBL5536694 0.80 LMNA (0.46) LMNAL3MBTL1TDP1KMT2AALDH1A1
SCHEMBL436038 0.79 LMNA (0.56) LMNAL3MBTL1TDP1KMT2AALDH1A1
SCHEMBL14613398 0.79 LMNA (0.56) LMNAL3MBTL1TDP1KMT2AALDH1A1
SCHEMBL1134756 0.79 LMNA (0.56) LMNAL3MBTL1TDP1KMT2AALDH1A1
SCHEMBL5538590 0.79 LMNA (0.45) LMNAL3MBTL1TDP1KMT2AALDH1A1
SCHEMBL5544946 0.79 LMNA (0.45) LMNAL3MBTL1TDP1KMT2AALDH1A1
SCHEMBL10405191 0.77 LMNA (0.58) LMNAL3MBTL1TDP1KMT2AALDH1A1
SCHEMBL14582812 0.76 LMNA (0.53) LMNAL3MBTL1TDP1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 LMNA 4152/4885L3MBTL1 1931/4885TDP1 4666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.